Our study indicates the safety and efficacy of GBT in extremely obese patients particularly as a first step before a definitive anti-obesity operation. GBT appears to be a safe, tolerable, and potentially effective procedure for the initial treatment of morbid obesity.
Background: Gastric balloon therapy (GBT)is a temporay, nonsurgical treatment for obesity. This retrospective study evaluates safety and efficacy of GBT in obese patients. Methods: The BioEnterics® Intragastric Balloon (BIB) was endoscopically implanted into each patient’s stomach and inflated with saline (450–750 ml). Extraction was planned after 6 months. Data from 190 patients receiving GBT were evaluated. Mean weight was 168.4 – 58.9 kg (range 76.5–310.0) and mean BMI was 55.6 – 17.5 kg/m2 (range 27.0–95.7). Results: Mean weight loss at the time of balloon removal was 21.2 – 14.0 kg (range 0–80.0). The mean BMI loss and EBL (Excess BMI Loss) were 7.2 – 4.9 kg/m2 (range 0–28.9) and 30.1 – 26.4% (0–184.4), respectively. The most substantial weight and BMI loss was observed in the most massively obese patients. Minor complications at implantation were encountered in 2 cases (1.1%) due to leakage of the balloon, and in 3 cases at explantation (1.6%). No mortality or major complications such as gastric perforation or ulcers occurred. Of the 190 patients, 76 received subsequent surgery (40.0%). Of those, 7 patients had a BMI < 50 kg/m2 while all other patients where super-obese(BMI > 50 kg/m2). 58 patients (30.5%) with a BMI > 60 kg/m2 which had an extra ordinary high operation risk were able to receive subsequent surgical treatment because of a substantial weight loss and/or reduced comorbidity. Conclusion: GBT appears to be a safe, tolerable, and potentially effective procedure for the initial treatment of morbid obesity.
Hintergrund: Der temporÄre Einsatz eines Magenballons zur Behandlung der Adipositas Grad1 und 2 nimmt weltweit zu; bei der Adipositas Grad 3 wird der Magenballon als adjuvantes Hilfsmittel zur prÄoperativen Gewichtsreduktion implantiert. Ziel dieser retrospektiven Kohorten analyse ist, die Wirksamkeit des Magenballons auf Gewichtsreduzierung und das Risikoprofil der Methode zu evaluieren. Methoden: Retrospektive Kohortenanalysen aus 4 Adipositas-Zentren, in denen der Magenballon seit 2001 regelmÄßig implantiert wurde. Ergebnisse: Von Februar2001 bis April 2008 wurde bei 634 Patienten ein Magenballon implantiert (BIBTM Intragastric Balloon System; Allergan Medical, Irvine, CA, USA). Die Geschlechterverteilung war 31,5% MÄnnerzu 68,5% Frauen; das Durchschnittsalter betrug 41,5 Jahre. Das durchschnittliche Ausgangsgewicht lag bei 126 kg. Der initiale BMI bei Implantation des Magenballons war 42,5 kg/m2. Die Implantation der Prothese war in allen FÄllen unkompliziert. Der durchschnittliche Gewichtsverlust lag bei 20,75 kg bzw. 7,05 BMI-Punkten.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.